AstraZeneca and Daiichi Sankyo were clearly excited by data from a trial pitting their HER2 antibody-drug conjugate (ADC) Enhertu against Roche's rival Kadcyla when they reported top-line results ...

Bridgeport Latino community comes together after comedian makes comments at Trump rally Kamala Harris Scores Major Endorsement in Texas I’m 54 with a 35-year-old body. It all started because I ...

With just six days until Election Day 2024, Kamala Harris is cleaning up a dumpster fire of controversy courtesy of President Joe Biden. The president called Trump supporters 'garbage' on Tuesday ...

Trodelvy shows consistent efficacy in metastatic triple-negative breast cancer with a 27.8% ORR and 4.8 months PFS. Enhertu demonstrates promising results in HER2-low patients post-Trodelvy, achieving ...

For example, AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) brought in revenues of more than $2.5 billion for these partners in 2023, which was its fourth full year on the market.

Lola McEvoy is set to press the government upon the use of Enhertu after the death of Heather Sawyer - a Darlington grandmother who campaigned for the drug she believed would have extended her life.

The drug, called Enhertu, can give patients with a specific type of incurable breast cancer an extra six months to live on average. The health assessment body, NICE, is the only organisation ...

Enhertu is a combination of a chemotherapy drug and targeted therapy. This type of therapy differs from immunotherapy. Doctors prescribe Enhertu for certain types of breast, lung, and other ...

ENHERTU is indicated for patients with unresectable or metastatic NSCLC with activating HER2 mutations who have previously undergone systemic therapy. Credit: Nemes Laszlo/Shutterstock. Daiichi Sankyo ...

The FDA approved the first treatment for MASH in March this year. Image credit: Shutterstock/ Iurii Motov. Inventiva has secured up to €348m ($380m) in financing to help wrap up a Phase III trial for ...

The FDA has approved the use of AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate Enhertu for all HER2-positive solid tumours, in a first for both HER2 inhibitors and ADCs. Enhertu ...